Perrigo Company (Nasdaq:PRGO; TASE:PRGO) said today that it has begun shipping its generic version of conjunctivitis treatment Zaditor.
The ophthalmic solution, Ketotifen Fumarate ophthalmic solution, 0.025%, for topical administration to the eyes, is used for the temporary prevention of itching of the eye due to allergic conjunctivitis.
Estimated annual brand sales for the product during the last twelve months were $15 million, according to Wolters Kluwer data.
Perrigo chairman and CEO Joseph C. Papa said, "Perrigo is excited to launch into a new adjacent OTC category, ophthalmic."
Perrigo develops, manufactures and distributes OTC and generic prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. Perrigo says it is the world's largest manufacturer of OTC pharmaceutical products for the store brand market.
Perrigo shares fell 0.15% early in Nasdaq trading to $50.53.
Published by Globes [online], Israel business news - www.globes-online.com - on March 15, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010